Status and phase
Conditions
Treatments
About
This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal cancer
Full description
The regimen involves 3-week cycles with bevacizumab (7.5 mg/m2 on days 1) and fixed doses of sintilimab (200 mg on day 1) and chemotherapy. The primary endpoint is progression-free survival (PFS). Secondary endpoints are Objective response rate(ORR), Disease control rate(DCR), Overall survival(OS) and quality of life. Adverse events are monitored and graded according to the Common Terminology Criteria for Adverse Events version 4.0.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Sign written informed consent before implementing any experimental procedures
Over 18 years old
Histologically confirmed as colorectal adenocarcinoma without liver metastasis
At least one measurable lesion (RECIST 1.1)
Satellite stable (MSS) or low instability (MSI-L) or normal expression of DNA mismatch repair genes (pMMR)
ECOG PS score is 0-1
Progress after initial treatment or standard first-line treatment
Have sufficient organ and bone marrow function
Expected to survive for more than 3 months
Participants must have normal hematological test results, including：
Participants' prothrombin time (PT) must be less than 1.5 times the upper limit of normal values, and activated partial thromboplastin time (APTT) must be less than 1.5% of the upper limit of abnormal values
Participants must have normal laboratory test results, including：serum creatinine levels less than or equal to 1.5 times the upper limit of the normal reference range, or creatinine clearance rates greater than 50 ml/min
For participants without liver metastasis, their alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels must be less than or equal to 2.5 times the upper limit of the normal reference range, and their serum total bilirubin levels must be less than 1.5 times the upper limit of the normal reference range
For female subjects of childbearing age, a urine or serum pregnancy test with negative results should be conducted within 3 days prior to the first administration of the study drug (Day 1 of the first cycle)
If there is a risk of conception, all subjects must use contraceptive measures with an annual failure rate of less than 1% throughout the entire treatment period until 120 days after the last administration of the study drug
The subjects must agree to provide sufficient tumor tissue samples for PD-L1 expression detection
Exclusion criteria
Known presence of active central nervous system (CNS) metastases and/or cancerous meningitis
Microsatellite instability (MSI-H) or loss of expression of DNA mismatch repair genes (dMMR)
Currently participating in interventional clinical research treatment, or having received other research drugs or used research instruments for treatment within 4 weeks before the first administration
Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or drugs that stimulate or synergistically inhibit T cell receptors
Within 2 years prior to the first administration, there has been an active autoimmune disease requiring systemic treatment
Imaging shows tumor invasion/infiltration into large blood vessels, or researchers or radiologists assess a tendency towards bleeding
Have undergone major surgical treatment within 4 weeks prior to the initial administration of the investigational drug (excluding surgery for biopsy purposes) or are expected to undergo major surgery during the study period
Severe unhealed wounds, ulcers, or fractures
Undertook minor surgeries within 48 hours prior to the first receipt of the study drug
Currently or recently (within 10 days prior to receiving the first dose of the study drug) using aspirin (>325 mg/day) or other known nonsteroidal anti-inflammatory drugs that can inhibit platelet function for 10 consecutive days
Currently or recently (within 10 days prior to receiving the first dose of the study drug), using full dose oral or parenteral anticoagulants or thrombolytic agents for treatment for 10 consecutive days
There is a genetic tendency for bleeding or coagulation dysfunction, or a history of thrombosis
Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation
Individuals known to be allergic to the active ingredients of the study drug
Prior to commencing treatment, the individual has not fully recovered from any toxicity and/or complications caused by any intervention measures (i.e., ≤ grade 1 or baseline, excluding fatigue or hair loss)
Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1/2 antibody positive)
Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number detected is greater than the upper limit of normal value in the laboratory of the research center)
Pregnant or lactating women
The presence of any serious or uncontrollable systemic disease
Other situations that the researchers believe are not suitable for inclusion, or other potential risks that are not suitable for participation in this study
Primary purpose
Allocation
Interventional model
Masking
20 participants in 2 patient groups
Loading...
Central trial contact
Wang Gang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal